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Abstract:  Rosuvastatin  is  a  new  generation  HMG-CoA  reductase  inhibitor  which  exhibits  some  unique  pharmacologic  and 
pharmacokinetic properties. It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C 
lowering capacity and therefore has distinct advantages. We conducted a Medline literature search to identify rosuvastatin papers pub-
lished in English. In this review, we outline the pharmacology of rosuvastatin, highlighting its efficacy and safety. We also review the 
major clinical trials with reference to primary and secondary prevention, familial hypercholesterolaemia and comparison with other 
statins. Finally we address its place in clinical practice.
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Introduction
Ischaemic heart disease (IHD) is the leading cause of 
mortality worldwide and constitutes a major health 
burden.  According  to  World  Health  Organisation 
(WHO) statistics it accounts for 12.8% of deaths, with 
stroke and other cerebrovascular disease accounting 
for a further 10.8%. In the United Kingdom, data from 
the Health Surveys for England suggest that while 
mortality may be declining, cardiovascular disease 
morbidity continues to rise. Epidemiological studies 
have established a strong correlation between choles-
terol and the incidence of cardiovascular disease. The 
associated morbidity and mortality is positively corre-
lated to low density lipoprotein cholesterol (LDL-C) 
and inversely related to high density lipoprotein cho-
lesterol (HDL-C).1,2
Statins are 3-hydroxy-3-methylglutaryl coenzyme 
A (HMG CoA) reductase inhibitors that are effec-
tive in the reduction of total and LDL cholesterol.3 
A  number  of  large  randomized  control  trials  have 
demonstrated  unequivocally  that  lowering  LDL-C 
particularly with statins reduces the risk of cardiovas-
cular deaths and events.4 HMG CoA inhibitors have 
been shown to prevent initial cardiovascular events 
and subsequent cardiovascular events in ischaemic 
heart disease patients, irrespective of the cholesterol 
concentration.5,6 In addition to the beneficial choles-
terol  lowering  effects,  statins  improve  endothelial 
function, enhance stability of atherosclerotic plaques, 
and  inhibit  inflammatory  as  well  as  thrombogenic 
responses  in  arterial  walls.7  Furthermore  extensive 
post marketing surveillance has shown that long term 
statin therapy is generally well tolerated.8
The lipid lowering arms of Anglo-Scandinavian 
Cardiac  Outcomes  Trial  (ASCOT)  and Antihyper-
tensive  and  Lipid  Lowering  Treatment  to  Prevent 
Heart Attack Trial (ALLHAT) showed the benefit of 
statin therapy in primary prevention of cardiovascu-
lar events.9,10 The 4S study was the first study con-
clusively linking a statin with improved outcomes in 
patients with coronary heart disease. It established 
simvastatin as the most common LDL-C lowering 
treatment for patients with CHD in northern Europe.11 
Subsequently, more studies including results of the 
Treating to New targets (TNT) trial have shown that 
intensive  lipid  lowering  (atorvastatin  80  mg)  sig-
nificantly  reduces  the  risk  of  recurrent  cardiovas-
cular  events  compared  to  standard  lipid  lowering 
(  atorvastatin 10 mg) in stable CHD patients.12 Other 
clinical trials using various statins have confirmed 
similar beneficial effects for ameliorating cardiovas-
cular risk in specific groups such as patients with dia-
betes, heart failure and renal failure. Early detection 
and treatment with statins has been shown to reduce 
morbidity and mortality in those with heterozygous 
familial hypercholesterolaemia.13
The reduction in cardiovascular events from sta-
tin therapy is proportional to the LDL-C reduction. 
A 1.0 mmol/L reduction in LDL-C results in a 20% 
decrease in major coronary events and revasculari-
sation.14 Larger reductions in LDL-C are associated 
with greater reductions in cardiovascular events, so 
more potent statins result in greater cardiovascular 
risk reduction. The drive towards more stringent goals 
for LDL-C lowering in cardiovascular risk prevention 
has brought high impact statin therapy into focus.12 
Different  statins  have  varying  effects  on  LDL-C 
reduction  with  rosuvastatin  producing  the  greatest 
reduction and fluvastatin the least.15 Statins vary in 
their lipophilicity and metabolism. These affect their 
extrahepatic tissue penetration and drug interactions 
with potential safety implications. Rosuvastatin which 
is a new generation HMG-CoA reductase inhibitor 
exhibits  some  unique  pharmacologic  and  pharma-
cokinetics properties.16 It has low extrahepatic tissue 
penetration, low potential for CYP3A4 interactions 
and substantial LDL-C lowering capacity and may 
therefore have some advantages. Its potential impact 
in primary and secondary prevention of cardiovascu-
lar disease in different groups including heart failure, 
elderly, renal failure and diabetes, and also in combi-
nation with other lipid lowering drugs is the subject 
of ongoing clinical studies.
In this review, we will outline the pharmacology of 
rosuvastatin; highlight its efficacy and safety. We will 
also review clinical studies with reference to primary 
and secondary prevention, familial hypercholestero-
laemia and comparison with other statins. Finally we 
will address its place in clinical practice.
pharmacology
Rosuvastatin is a fully synthetic HMG-CoA reductase 
inhibitor. Other HMG-CoA reductase inhibitors are 
either natural, mevinic acid derived (lovastatin, simvas-
tatin, pravastatin) or synthetic, heptenoic acid derived 
(atorvastatin, fluvastatin). Rosuvastatin belongs to a rosuvastatin—what role in cardiovascular disease prevention?
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new generation of methane-  sulphonamide   pyrimidine 
and  N-methane  sulfonyl  pyrrole-substituted  3,  5- 
dihydroxy-heptenoates.  Although  the  characteristic 
statin pharmacophore remains similar to other statins, 
the addition of a stable polar methane-sulphonamide 
group provides low lipophilicity and enhanced ionic 
interaction with HMG-CoA reductase enzyme thus 
improving its binding affinity to this enzyme.16–18
pharmacodynamics
Rosuvastatin  competitively  inhibits  HMG-CoA 
reductase  enzyme  selectively  and  reversibly.  This 
enzyme converts HMG-CoA to mevalonic acid in the 
cholesterol biosynthetic pathway which is the rate lim-
iting step in cholesterol synthesis. Rosuvastatin there-
fore decreases hepatic sterol synthesis, which, in turn, 
leads to a decreased concentration of hepatocellular 
cholesterol.  Hepatocytes  respond  to  this  decreased 
intracellular  cholesterol  concentration  by  increased 
synthesis of LDL receptors to enhance hepatic LDL 
reuptake from the circulation. The net result of this 
process is an increased fractional catabolism of LDL 
which reduces serum LDL-C concentration and total 
cholesterol.19,20 Statins also reduce production of ApoB 
leading to reduced hepatic output of very low density 
lipoprotein cholesterol (VLDL-C) and triglycerides.21 
In patients with homozygous familial hypercholes-
terolaemia,  rosuvastatin  decreases  LDL-C  despite 
absence of functional LDL receptors. This may be sec-
ondary to marked inhibition of cholesterol synthesis 
which decreases LDL production. Rosuvastatin has 
demonstrated comparable reductions in triglyceride 
(TG) concentrations to other statins with the greatest 
benefit seen in patients with high baseline TG levels. 
Studies have shown rosuvastatin to increase HDL-C 
by 8%–12% with no clear relationship between the 
dose and response, although the increase is greatest 
in patients with low baseline HDL-C levels.22,23 This 
may be due to reduction of cholesterol ester transfer 
protein (CETP).24
The affinity of rosuvastatin for the active site of 
the enzyme is four times greater than the affinity of 
HMG-CoA for the enzyme. It has the highest affin-
ity for HMG-CoA reductase among statins marketed 
in Europe. This high affinity coupled with tight ionic 
interaction result in a slow recovery of enzyme activ-
ity after removal of rosuvastatin.25 Since it is a hydro-
philic statin, rosuvastatin relies on the organic anion 
transporting  polypeptide-1B1  (OATP-1B1),  which 
is strongly expressed on the hepatocyte basolateral 
membrane, as the key mechanism for active transport 
into hepatocytes. Its affinity for OATP-1B1 is com-
parable to atorvastatin but significantly greater than 
pravastatin or simvastatin. Rosuvastatin is therefore 
primarily distributed to hepatocytes while peripheral 
concentrations are low.26
As  observed  with  other  statins,  rosuvastatin 
has  pleiotropic  effects  independent  of  HMG-CoA 
reductase inhibition. These include improvements in 
endothelial  function,  anti-inflammatory,  antithrom-
botic  and  anti-oxidant  effects.27  Rosuvastatin  and 
other statins improve endothelial function by increas-
ing  the  production  of  endothelial  nitric  oxide  and 
reducing the production of oxygen derived free radi-
cals. This in turn reduces endothelial dysfunction that 
has been implicated in atherosclerosis.   Rosuvastatin 
reduces high sensitivity C reactive protein (hsCRP) 
which is a marker of inflammation and an indepen-
dent cardiovascular risk predictor and other inflam-
matory    markers.28  Rosuvastatin  inhibits  platelet 
aggregation to leukocytes which inhibit formation of 
clots in injured endothelium.29
pharmacokinetics
The oral bioavailability of rosuvastatin is 20%, which 
is comparable to atorvastatin, pravastatin and fluvas-
tatin, and qualitatively higher than simvastatin and 
lovastatin. After a single oral dose the peak plasma 
concentration is reached at 5 hours. This is longer 
than other HMG-CoA inhibitors which achieve maxi-
mum plasma concentrations in less than 3 hours. In 
compiled data from pharmacokinetic trials, the peak 
plasma concentration and area under the concentra-
tion time curve show a largely linear relationship as 
the dose of rosuvastatin increases from 5 to 80 mg. 
Food intake decreases the rate of absorption of rosu-
vastatin by 20% but not the extent of absorption. This 
does  not  reduce  the  cholesterol  lowering  potency; 
therefore rosuvastatin can be taken with or without 
food, and in the morning or evening.16,17,30
Approximately  90%  of  rosuvastatin  is  protein 
bound mainly to albumin; other statins have approxi-
mately 95% protein binding except pravastatin which 
has a lower protein binding of 50%. The mean vol-
ume  of  distribution  is  134  litres  in  steady  state. 
  Rosuvastatin is less lipophilic than other statins such Luvai et al
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as atorvastatin and simvastatin but more lipophilic 
than  pravastatin.  Penetration  of  statins  into  extra- 
hepatic  tissues  occurs  by  passive  diffusion  and  is 
dependent  on  their  lipophilicity. This  has  implica-
tions on their muscle safety as increased rhabdomy-
olysis was reported in patients on lipophilic agents 
like cerivastatin and lovastatin.31,32
Human  hepatocyte  studies  indicate  that  rosu-
vastatin is a poor substrate for metabolism by cyto-
chrome P450 and hence 90% of the drug is excreted 
unchanged. CYP2C9 is the main isoenzyme involved 
in metabolism with minimal effect from CYP2C19.33 
Rosuvastatin  is  metabolised  to  an  N-desmethyl 
metabolite which is less potent than the parent drug 
in inhibiting HMG-CoA reductase activity. The par-
ent  drug  rosuvastatin  is  responsible  for  approxi-
mately 90% of plasma HMG-CoA inhibitor activity. 
Rosuvastatin is less likely to cause metabolic drug to 
drug interactions since it has limited metabolism by 
CYP isoenzymes. Other HMG-CoA reductase inhibi-
tors such as   atorvastatin and simvastatin are metabo-
lised via CYP3A4. Their plasma concentrations are 
increased by inhibitors of CYP3A4 such as itracon-
azole,  protease  inhibitors  and  macrolide  antibiot-
ics.16,30,33 Table 2 compares the pharmacokinetics of 
different statins.
Rosuvastatin has a plasma half life of 19 hours 
which is longer than atorvastatin (15 hours) and sim-
vastatin (2–3 hours). It is primarily eliminated in the 
faeces  (90%)  compared  with  10%  renal  excretion. 
Approximately 72% of absorbed rosuvastatin is elim-
inated in bile and 28% via renal excretion.33
clinical Trials
There have been a number of clinical studies eval-
uating rosuvastatin on its own, against placebo and 
against other statins in various clinical settings.
rosuvastatin in primary prevention
Clinical  studies  have  demonstrated  the  benefits  of 
statins in primary prevention. This is believed prin-
cipally to be secondary to reduction in LDL-C, high 
sensitivity C-reactive protein (hsCRP) and elevation 
of HDL-C though other effects are recognised. The 
Cholesterol Treatment Trialists’ Collaborators (CTT) 
meta-analysis established that a 1 mmol/L reduction 
in LDL cholesterol results in a 20% reduction in car-
diovascular risk.14 The benefit of statins in low risk 
populations was demonstrated in the Management of 
Elevated Cholesterol in the Primary Prevention Group 
of Adult Japanese (MEGA) study where reduction of 
cholesterol using pravastatin 10 mg reduced cardio-
vascular events by 33%.35
JUPITER  (Justification  for  the  Use  of  Sta-
tins  in  Prevention:  an  Intervention  Trial  Evaluat-
ing  Rosuvastatin)  marked  an  important  juncture 
in primary cardiovascular disease prevention with 
statins. The participants had a mean Framingham 
risk score at baseline of 11.6% and would other-
wise not have qualified for lipid lowering therapy. 
They were apparently healthy individuals with nor-
mal levels of LDL-C (,3.4 mmol/L) and increased 
hsCRP (.2 mg/L). The hsCRP threshold value of 
2  mg/L  is  the  approximate  median  hsCRP  value 
after 30 days of statin therapy. It originated from 
secondary  prevention  trials  and  in  particular  the 
PROVE-IT-TIMI-22  (Pravastatin  or  Atorvastatin 
Evaluation  and  Infection  Therapy—Thrombolysis 
In Myocardial Infarction) and A to Z (Aggrastat to 
Zocor) which showed that achieving this level of 
hsCRP was associated with improved cardiovascu-
lar outcomes.36 JUPITER was a randomised, double 
blind, placebo-matched, multicentre trial conducted 
at  1315  sites  in  26  countries.  17,802  participants 
received either 20 mg of rosuvastatin, or matched 
placebo, and were followed up every six months. 
12 months into the study, the rosuvastatin group had 
a  50%  lower  median  LDL-C,  37%  lower  median 
hsCRP  and  17%  lower  median    triglyceride  level 
(P , 0.001 for all three   comparisons) which per-
sisted to study   completion. The observed increase in 
HDL-C was transient. Results showed that rosuvas-
tatin was associated with a significant reduction in 
first major cardiovascular events (HR 0.56; 95% CI, 
0.46 to 0.69; P , 0.00001) which was the primary 
endpoint. Reductions were further seen in the inci-
dence of the individual components of the trial end 
point including myocardial infarction (54%), stroke 
(48%),  arterial  revascularisation  (47%),  unstable 
angina and death from cardiovascular causes. This is 
important as up to 50% of all myocardial infarctions 
and strokes occur in patients with LDL cholesterol 
concentrations  that  are  considered  normal.37  The 
benefits were largely similar for men and women, 
and were observed in all subgroups including age, 
ethnicity,  region  and  cardiovascular  risk  score. rosuvastatin—what role in cardiovascular disease prevention?
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  Previously, there has been limited data on statin ben-
efits in women, black and Hispanic patients.
Since  the  results  of  JUPITER  were  initially 
  published, several secondary subgroup analyses of 
the study population have been reported. Participants 
with a 10 year low baseline risk (,5%) benefited 
less than those with risk .5%. Participants with a 
10 year intermediate baseline risk by Framingham 
(5%–20%)  experienced  incremental  absolute  risk 
reductions  that  were  proportional  to  their  global 
risk.38 In a   different subgroup analysis, participants 
at  high  global  risk  (10  year  Framingham  score 
.20%) showed no   additional benefit for the com-
bined endpoint of   myocardial infarction, stroke and 
Table 1. Trial acronyms.
Acronym Full meaning
AFCApS Air Force/Texas Coronary Atherosclerosis prevention Study
ALLHAT Antihypertensive and Lipid Lowering Treatment to prevent Heart Attack Trial
ASCOT Anglo-Scandinavian Cardiac Outcomes Trial
ANDrOMEDA A raNdomized, Double-blind, double-dummy, multicentre, phase IIIb, parallel-group study to 
compare the efficacy and safety of Rosuvastatin (10 mg and 20 mg) and atOrvastatin (10 mg and 
20 mg) in patiEnts with type 2 DiAbetes mellitus
ASTErOID A Study to Evaluate the Effect of rosuvastatin on Intravascular Ultrasound-derived Coronary 
Atheroma Burden
A to Z Aggrastat to Zocor
AUrOrA A Study to Evaluate the Use of rosuvastatin in Subjects on regular Haemodialysis: An 
Assessment of Survival and Cardiovascular Events
CArDS Collaborative Atorvastatin Diabetes Study
CENTAUrUS Comparison of the Effects Noted in The ApoB:ApoA-I ratio Using rosuvastatin or Atorvastatin in 
patients with Acute Coronary Syndrome
COrALL Cholesterol Lowering Effects of rosuvastatin compared with Atorvastatin in patients with type 2 
diabetes
COrONA Controlled rosuvastatin Multinational Trial in Heart Failure
COSMOS Coronary Atherosclerosis Study Measuring Effects of rosuvastatin Using Intravascular 
Ultrasound in Japanese Subjects
4D Deutsche Dialyse Diabetes Study
GEOSTAT Hepatic Metabolism and Transporter Gene variants Enhance response to rosuvastatin in 
patients with Acute Myocardial Infarction
GISSI-HF Gruppo Italiano per lo Studio della Supravvivenza nell’Insufficienza cardiaca
IDEAL Incremental Decrease in Endpoints through Aggressive Lipid Lowering
JUpITEr Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin
LIpID Long-term Intervention with pravastatin in Ischaemic Disease
MEGA Management of Elevated Cholesterol in the primary prevention Group of Adult Japanese
METEOr Measuring Effects on Intima Media Thickness: an Evaluation of rosuvastatin
MIrACL Myocardial Ischaemia reduction with Aggressive Cholesterol Lowering
OrION Outcome of rosuvastatin Treatment on Carotid Artery Atheroma: a Magnetic resonance Imaging 
Observation
pLUTO paediatric Lipid reduction Trial of rosuvastatin
prOvE-IT pravastatin or Atorvastatin Evaluation and Infection Therapy
pULSAr prospective Study to Evaluate Low Doses of Atorvastatin and rosuvastatin
4S Scandinavian Simvastatin Survival Study
SATUrN Study of Coronary Atheroma by Intravascular Ultrasound: Effect of rosuvastatin versus 
Atorvastatin
SHArp Study of Heart and renal protection
SpACErOCKET Secondary prevention of Acute Coronary Events – reduction of Cholesterol to Key European 
Targets Trial
STELLAr Comparison of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and 
pravastatin Across Doses
TNT Treating to New Targets
UrANUS Use of rosuvastatin versus Atorvastatin in type 2 diabetes mellitus
wOSCOpS west of Scotland Coronary prevention StudyLuvai et al
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  cardiovascular death (HR 0.50; 95% CI, 0.27 to 0.93) 
when compared with subjects who had an intermedi-
ate Framingham risk score.39
Another series of sub analyses have looked at lipid 
profiles and hsCRP particularly in relation to residual 
cardiovascular risk. In all of them, participants who 
achieved low concentrations of hsCRP in addition to 
low values of the lipid parameters of interest had the 
best outcome. When hsCRP is included in enrolment 
of primary prevention, rosuvastatin produced greater 
benefit when compared with other statins.40
These  results  compare  favourably  with  other 
primary  prevention  trials  using  different  statins. 
WOSCOPS (West of Scotland Coronary Prevention 
Study) showed that pravastatin 40 mg in men with 
moderate  hypercholesterolaemia  reduced  incidence 
of myocardial infarction and cardiovascular death by 
31%.41  Similarly, AFCAPS  (Air  Force/Texas  Coro-
nary Atherosclerosis Prevention Study) demonstrated 
that lovastatin 20–40 mg daily reduced risk of first 
major coronary event by 37% in men and women with 
average  LDL-C  and  below  average  HDL-C  when 
compared with placebo.42 In the ASCOT lipid low-
ering arm, atorvastatin 10 mg reduced the incidence 
of  myocardial  infarction,  stroke  and  cardiovascular 
death by 36% compared to placebo.9 Figure 1 shows 
the CHD event reduction in primary prevention trials.
rosuvastatin in secondary prevention
The  beneficial  effects  of  statin  therapy  in  patients 
with ischaemic heart disease are well known. The 4S 
study showed that simvastatin 20 mg to 40 mg daily 
significantly  reduced  major  coronary  events,  coro-
nary death and overall mortality in patients post-MI 
or those with ischaemic heart disease.43 In the LIPID 
study  (Long-term  Intervention  with  Pravastatin  in 
Ischaemic Disease), pravastatin 40 mg reduced car-
diovascular  events  and  mortality  in  patients  with 
history of myocardial infarction or unstable angina 
with different baseline lipid profiles.44 Other studies 
Cardiovascular event rates in statin trials
Primary prevention statin trials
E
v
e
n
t
 
r
a
t
e
 
×
 
1
0
0
 
p
a
t
i
e
n
t
/
y
r
3
2
CARDS
atorvastatin
AFCAPS
lovastatin
ASCOTT
atorvastatin
WOSCOPS
pravastatin
JUPITER
rosuvastatin
0
Placebo
Statin 1
1.5
2.5
0.5
Figure 1. CHD event rate in primary prevention trials.
Table 2. pharmacokinetics of statins.
comparative pharmacokinetics of statins
parameter Rosuvastatin Atorvastatin simvastatin pravastatin Fluvastatin pitavastatin Lovastatin
Tmax (h) 3 2–3 1.3–2.4 0.9–1.6 0.4–2.1 0.6–0.8 2–4
Bioavailability 20 12 5 18 24 80 5
Lipophilicity No Yes Yes No Yes Yes Yes
protein  
binding
88 80–90 94–98 43–55 .98 96 95
Metabolism Minimal 
CYp2C9 
CYp2C19 
Biliary  
excretion
CYp3A4 CYp3A4 Sulfation 
Biliary  
& urine  
excretion
CYp2C9 Minimal 
CYp2C8 
CYp2C9
CYp3A4
Metabolites Active (minor) Active Active Inactive Inactive Active  
(minor)
Active
T1/2 (h) 19 15 2–3 1.3–2.8 1.2 10–11 2.9
Urinary  
excretion
10 2 13 20 6 NA 10
Faecal  
excretion
90 70 58 71 90 90 83
note: Data from Soran et al.34
Abbreviations: Tmax, time to peak plasma concentration; T1/2 (h), half life.rosuvastatin—what role in cardiovascular disease prevention?
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have also established the benefits of treatment after 
  myocardial infarction.
a) Stable coronary heart disease (CHD)/Arrest 
and regression of atherosclerosis
The TNT  trial  comparing  atorvastatin  80  mg  with 
  atorvastatin  10  mg,  investigated  whether  inten-
sive  treatment  to  achieve  LDL-C  ,1.81  mmol/L 
was associated with better outcomes. Mean LDL-C 
of 2 mmol/L was realised with intensive treatment. 
A relative risk reduction of 22% was achieved for 
the  primary  outcome  which  was  the  occurrence 
of a first major cardiovascular event.12 The IDEAL 
study  (Incremental  Decrease  in  Endpoints  through 
  Aggressive Lipid Lowering) compared the effect of 
atorvastatin 80 mg and simvastatin 20 mg on cardio-
vascular outcomes. There were significant reductions 
in non fatal acute myocardial infarction and in other 
secondary composite endpoints, with no difference 
in  cardiovascular  or  all-cause  mortality.  Statistical 
significance was not demonstrated for the prespeci-
fied primary clinical outcome which was time to first 
occurrence of major coronary event.45 In as much as 
there have been no clinical outcome data for second-
ary prevention with rosuvastatin, a number of studies 
have compared their effect on surrogate markers and 
achievement of treatment goals. The STELLAR study 
(Comparison of the Efficacy and Safety of Rosuvasta-
tin Versus Atorvastatin, Simvastatin, and Pravastatin 
Across Doses) showed that at different doses, rosuvas-
tatin reduced total cholesterol better than other statins, 
and triglycerides better than simvastatin and pravas-
tatin. Additionally a larger proportion of rosuvasta-
tin patients achieved National Cholesterol Education 
Program Adult Treatment Panel III (NCEP ATP III) 
LDL-C targets when compared with atorvastatin.46,47 
PULSAR (Prospective Study to Evaluate Low Doses 
of  Atorvastatin  and  Rosuvastatin)  showed  that  in 
hypercholesterolaemic patients with vascular occlu-
sive disease rosuvastatin 10 mg was better than ator-
vastatin 20 mg at reducing LDL-C, improving other 
lipid parameters and enabling achievement of US and 
European treatment goals.47–49 Table 3 shows current 
LDL-C treatment targets.
Several  studies  have  suggested  that  reduction 
in plaque volume is linked to the clinical outcome. 
ASTEROID  (A  Study  to  Evaluate  the  Effect  of 
Rosuvastatin  on  Intravascular  Ultrasound-derived 
  Coronary  Atheroma  Burden)  investigated  the 
impact of high dose rosuvastatin on regression of 
atherosclerosis. The results showed that rosuvasta-
tin 40 mg produced significant reduction in LDL-C 
(53% from baseline; P , 0.001), increase in HDL-C 
(14.7% from baseline; P , 0.001) and regression 
of atheroma volume in the most diseased coronary 
arteries in 78% of participants. A median reduction 
of 6.8% in atheroma volume was recorded by IVUS 
(intravascular ultrasound). It must be noted that the 
study was non-comparative and open label.50 Other 
studies including ORION (Outcome of Rosuvastatin 
Treatment on Carotid Artery Atheroma: a Magnetic 
Resonance  Imaging  Observation)  and  METEOR 
(Measuring  Effects  on  Intima  Media  Thickness: 
an  Evaluation  of  Rosuvastatin)  demonstrated  that 
rosuvastatin 40 mg achieved a 49% LDL-C reduc-
tion and slowed progression of atherosclerosis as 
assessed by carotid intima-media thickness (CIMT) 
but did not result in regression of CIMT. The lack 
of  plaque  regression  may  have  occurred  because 
low risk patients with minimal subclinical carotid 
atherosclerosis were used in the study. The COS-
MOS (Coronary Atherosclerosis Study Measuring 
Effects of Rosuvastatin Using Intravascular Ultra-
sound in Japanese Subjects) study found that rosu-
vastatin achieved significant reduction of coronary 
plaque volume with good safety in stable Japanese 
CHD patients.51,52 The recently concluded SATURN 
(Study of Coronary Atheroma by Intravascular Ultra-
sound: Effect of Rosuvastatin versus Atorvastatin) 
Table 3. Current LDL-C treatment goals.
Guideline Risk Target
ESC very high risk 
 
 
High risk 
Moderate risk
,1.8 mmol/L or  
50% reduction if  
target unachievable 
,2.5 mmol/L 
,3 mmol/L
JBS 2 High risk 2 mmol/L
NCEp ATp III CHD 
$2 risk factors 
0–1 risk factors
,100 mg/dL  
(2.6 mmol/L) 
,130 mg/dL  
(3.4 mmol/L) 
,160 mg/dL  
(4.2 mmol/L)
Abbreviations:  ESC,  European  Society  of  Cardiology;  JBS  2,  Joint 
British Societies Guidelines on prevention of Cardiovascular Disease 
in  Clinical  practice;  NCEp  ATp  III,  National  Cholesterol  Education 
programme Adult Treatment panel III.Luvai et al
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study compared maximal doses of rosuvastatin and 
atorvastatin on coronary atheroma. It reported that 
although rosuvastatin achieved lower LDL-C and 
higher HDL-C, both agents produced similar per-
centage reduction in atheroma volume.53
b) Acute coronary syndrome (ACS)
The  NCEP  ATP  III  guidelines  recommend  that 
intensive statin treatment should be used in patients 
admitted with acute coronary syndrome.47 The Euro-
pean Society of Cardiology (ESC) and the American 
College  of  Cardiology  (ACC)  have  recommended 
LDL-C levels of 1.8 mmol/L as the optimal target 
for very high risk patients (established CHD, type I 
diabetes with end organ damage, moderate to severe 
chronic  kidney  disease  (CKD)  or  a  SCORE  level 
.10%).48 Several studies have provided evidence of 
the   additional LDL-C lowering achieved by intensive 
statin therapy.
The PROVE-IT study found that intensive treat-
ment  with  atorvastatin  80  mg  was  better  than 
pravastatin 40 mg at preventing death and major car-
diovascular events following ACS.54 The A to Z study 
which compared 40 mg and 80 mg of simvastatin 
demonstrated a benefit which did not reach statistical 
significance, while the MIRACL (Myocardial Ischae-
mia Reduction with Aggressive Cholesterol Lower-
ing) study showed that early intensive treatment with 
atorvastatin 80 mg after ACS led to a 16% reduction 
in death, acute MI, unstable angina and cardiac arrest, 
compared with placebo.55 Meta-analyses of intensive 
statin trials have also shown that intensive treatment 
provides benefit above lower intensity treatment in 
prevention of myocardial infarction and strokes in 
patients with known coronary disease irrespective of 
the baseline LDL-C. The CENTAURUS (Comparison 
of the Effects Noted in The ApoB:ApoA-1 ratio Using 
Rosuvastatin or Atorvastatin in Patients with Acute 
Coronary Syndrome) study showed that 20 mg rosu-
vastatin produced similar changes in ApoB:ApoA-1 
ratio at 3 months when compared with atorvastatin 
80 mg. Previous studies have identified ApoB:ApoA-1 
ratio as an important predictor of myocardial infarc-
tion. In the same study rosuvastatin 20 mg achieved 
similar LDL-C reduction as atorvastatin 80 mg. This 
study therefore showed that rosuvastatin 20 mg is 
as effective as atorvastatin 80 mg in intensive statin 
therapy.56 In SPACEROCKET (Secondary Prevention 
of Acute Coronary Events—Reduction of Cholesterol 
to Key European Targets Trial), a larger proportion of 
patients on rosuvastatin 10 mg achieved ESC, ACC 
and  American  Heart  Association  (AHA)  optimal 
LDL-C target of less than 1.81 mmol/L when com-
pared to those on simvastatin 40 mg. A crucial obser-
vation of this study was that in both treatment arms, 
most patients did not achieve these targets, highlight-
ing the importance of intensive statin therapy to meet 
these  goals.  The  superior  lipid  lowering  effect  of 
rosuvastatin makes it a good candidate for intensive 
lipid lowering.57
rosuvastatin in women
Previous primary prevention trials have poorly dem-
onstrated reduction in coronary events in women. In 
JUPITER the relative risk reduction in the primary 
end point and overall mortality was similar in men 
and women. Although women benefited more than 
men with regard to revascularisation/unstable angina, 
no significant benefit was seen for myocardial infarc-
tion, stroke or death from cardiovascular causes.58
rosuvastatin in the elderly
Randomised  control  trial  (RCT)  data  are  limited 
regarding statin efficacy in the elderly. 5695 partici-
pants from JUPITER were .70 years at recruitment. 
They accounted for 49% of the confirmed primary 
end points in the trial. Analysis of this group showed 
an absolute risk reduction of the primary end point 
48% greater than that observed in younger subjects. 
There were no serious safety concerns raised for this 
age group compared with younger subjects.59
rosuvastatin in renal disease
Advanced  kidney  disease  is  associated  with  high 
cardiovascular morbidity and death. RCT evidence 
has shown an inconsistent relationship between car-
diovascular  outcome  and  LDL-C  in  haemodialysis 
patients.  WOSCOPS  showed  benefit  only  in  mild 
stages of CKD (eGFR . 60 mL/min per 1.73 m2). 
In JUPITER, participants with moderate CKD ben-
efited as much as those with preserved renal function 
in terms of primary end point reduction and faired 
better for all-cause mortality.60
AURORA (A Study to Evaluate the Use of Rosu-
vastatin  in  Subjects  on  Regular  Haemodialysis: 
An  Assessment  of  Survival  and  Cardiovascular rosuvastatin—what role in cardiovascular disease prevention?
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Events) investigated the effects of rosuvastatin on 
  cardiovascular risk in haemodialysis patients. It was 
a randomised, double blind, placebo-matched, multi-
centre trial involving 2776 patients aged 60–80 years. 
Good median reductions were achieved in LDL-C 
(42.9%),  total  cholesterol  (26.6%),  triglycerides 
(16.2%) and hsCRP (11.5%). Despite these reduc-
tions, there was no significant effect of treatment on 
the composite primary end point (time to a major 
cardiovascular event) or its individual components 
(nonfatal myocardial infarction, nonfatal stroke, or 
death from cardiovascular causes). This lack of effi-
cacy was seen in all prespecified subgroups includ-
ing  diabetes,  known  CHD,  hypertension,  elevated 
hsCRP and high HDL-C. Thus, no relationship was 
demonstrated between cardiovascular end points and 
either baseline or follow up LDL-C. A further evalu-
ation of secondary outcomes showed no reduction 
in all-cause mortality or non-cardiovascular death.61 
Similar  results  have  been  obtained  from  the  4D 
study which looked at atorvastatin.62 In contrast to 
these studies, the SHARP (Study of Heart and Renal 
Protection)  study  which  compared  a  combination 
of simvastatin 20 mg and ezetimibe 10 mg to pla-
cebo, found 17% reduction in major atherosclerotic 
events per 0.85 mmol/L reduction in LDL-C in CKD 
patients.63 The implication of these findings is that 
some of the cardiovascular morbidity and mortality 
in haemodialysis patients may not be mediated by 
atherogenic processes.
rosuvastatin in diabetes
Type  2  diabetes  is  associated  with  increased  risk 
of  coronary  heart  disease.  In  the  UK  Prospective 
  Diabetes  Study  (UKPDS),  every  1  mmol/L  incre-
ment in LDL-C was associated with a 57% increase 
in  relative  risk  of  coronary  heart  disease.  Further-
more, the LDL-C of diabetic patients predicted their 
risk of stroke.64 CARDS (Collaborative Atorvastatin 
Diabetes Study) showed that atorvastatin 10 mg led 
to a reduction in cardiovascular events and strokes in 
diabetes patients without high HDL-C and no prior 
history of cardiovascular disease.65 This has strength-
ened the need for statin therapy for primary preven-
tion in diabetes patients. Sub-group analyses of 4S 
showed the benefits of simvastatin in reducing major 
coronary  events  and  revascularisation  in  diabetic 
patients with coronary heart disease. However, the 
reduction in total and cardiovascular mortality was 
not   significant due to the small sample size.66
A randomised double blind double-dummy, multi-
centre, phase IIIb, parallel-group study to compare the 
efficacy and safety of rosuvastatin (10 mg and 20 mg), 
and atorvastatin (10 mg and 20 mg) in patients with 
type  2  diabetes  mellitus  (ANDROMEDA)  showed 
that  rosuvastatin  produced  greater  reductions  in 
LDL-C, ApoB and total cholesterol when compared 
with equal doses of atorvastatin. A greater proportion 
of patients on rosuvastatin achieved European LDL-C 
goals compared to those on atorvastatin.67 The COR-
ALL (Cholesterol Lowering Effects of Rosuvastatin 
compared with Atorvastatin in patients with type 2 
diabetes)  study  showed  that  rosuvastatin  produced 
greater reductions in ApoB:ApoA-1 ratios, LDL-C 
and total cholesterol in diabetic patients with mod-
erate  dyslipidaemia.68  The  superior  effect  of  rosu-
vastatin compared with atorvastatin in reduction of 
LDL-C was also demonstrated in the URANUS (Use 
of Rosuvastatin versus Atorvastatin in type 2 diabetes 
mellitus) study.69
Familial hypercholesterolaemia (FH)
Many FH guidelines recommend a .50% reduction 
of LDL-C in heterozygous FH. Studies comparing dif-
ferent lipid lowering regimens demonstrate that only 
high impact therapy with rosuvastatin 40 mg or ator-
vastatin 80 mg achieves this goal when administered 
as monotherapy.70 In all other circumstances, combi-
nation therapy with ezetimibe, bile acid sequestrants, 
fibrates, nicotinic acid or fish oils is often required.71 
There are no randomised control trial (RCT) outcome 
data with these combinations in FH. Whereas it is 
accepted that LDL apheresis and plasmapheresis are 
suitable treatments for homozygous FH, there are no 
RCTs comparing LDL apheresis and drug treatment 
alone. The use of LDL apheresis in heterozygous FH 
patients is thus unclear and at present maximal drug 
therapy is the preferred treatment.
rosuvastatin in heart failure
The  CORONA  (Controlled  Rosuvastatin  Multina-
tional Trial in Heart Failure) investigated the effect of 
rosuvastatin 10 mg in patients with New York Heart 
Association functional class II-IV systolic heart fail-
ure  from  ischaemic  heart  disease.  The  CORONA 
study did not establish any reduction in composite Luvai et al
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cardiovascular outcome and death despite favourable 
effects on LDL-C, triglycerides, HDL-C and CRP. 
The use of rosuvastatin did however reduce hospitali-
sation from cardiovascular causes.72 A similar trend 
was found in the GISSI-HF study in which only 40% 
of patients had ischaemic heart failure. In the GISSI 
HF (Gruppo Italiano per lo Studio della Supravvi-
venza nell’Insufficienza cardiac) study, rosuvastatin 
10 mg had no effects on primary and secondary end-
points when compared with placebo.73 The two stud-
ies show that rosuvastatin did not have extra benefit 
in reduction of cardiovascular mortality in patients 
with ischaemic and non-ischaemic heart failure.
rosuvastatin in children
Studies in children with heterozygous FH have shown 
the  safety  and  efficacy  of  statins,  including  their 
effect on carotid intima thickness and arterial flow 
mediated dilation.74 PLUTO (Paediatric Lipid Reduc-
tion Trial of Rosuvastatin) investigated the efficacy 
and  safety  of  incremental  doses  of  rosuvastatin  in 
achieving LDL-C treatment targets of ,110 md/dL 
(2.87 mmol/L). A daily dose of rosuvastatin 5, 10 and 
20 mg lowered LDL-C by 38, 45 and 50% respec-
tively, with 40% of participants achieving the target. 
68% of participants achieved the less stringent goal 
of LDL-C ,130 mg/dL (3.4 mmol/L). This is far bet-
ter than the adult FH population in who only 22% and 
37% will achieve this LDL-C on 20 and 40 mg of 
rosuvastatin respectively. The effects on other lipid 
parameters and safety were consistent with other sta-
tin studies in adults and children.75
Stroke
JUPITER  showed  a  51%  reduction  in  ischaemic 
stroke with rosuvastatin, though no beneficial effects 
were observed for transient ischaemic attacks or hae-
morrhagic strokes. These benefits were present in all 
patient groups including women, non smokers and 
other  low  risk  patients. There  was  a  39%  relative 
risk reduction of stroke per 1 mmol/L reduction in 
LDL-C. The beneficial effects were most marked for 
those who achieved LDL-C ,1.8 mmol/L and hsCRP 
,2 mg/L.40 Previous studies with other statins such 
as WOSCOPS and MEGA did not show significant 
reduction in stroke.41,35 Rosuvastatin not only reduces 
the risk of stroke as shown in JUPITER but also slows 
the rate of progression of carotid   atherosclerosis as 
observed  in  the  ORION  and  METEOR  studies.51 
There has not been any study investigating the effect 
of rosuvastatin in the secondary prevention of strokes 
in  patients  with  previous  history  of  stroke.  The 
SPARCL study showed that intensive statin therapy 
with atorvastatin 80 mg daily resulted in significant 
reduction in recurrent stroke.76 A secondary analy-
sis of the SPARCL study found that the effect was 
greater in patients with established carotid stenosis 
at baseline. Intensive therapy with rosuvastatin may 
yield similar benefits.
Highly Active Antiretroviral Therapy 
(HAArT)
HIV patients on highly active antiretroviral therapy 
are  increasingly found  to  have  hypercholesterolae-
mia and hypertriglyceridaemia. Prospective studies 
have also shown that these patients have increased 
incidence of cardiovascular events.77 Current guide-
lines  recommend  statins  to  treat  dyslipidaemia  in 
HIV patients on HAART. Since 90% of rosuvastatin 
is excreted unchanged in bile with only 10% metab-
olised by CYP2C9 and CYP2C19, rosuvastatin has 
minimal drug–drug interactions with most antiretro-
viral drugs metabolised by CYP3A4.78
Protease inhibitors such as ritonavir, saquinavir and 
atazanavir inhibit OATP-1B1 the transporter protein 
involved in the hepatic cell uptake of rosuvastatin. This 
leads to higher serum rosuvastatin concentrations in 
patients taking protease inhibitors. It is recommended 
that lower doses of rosuvastatin are used in patients 
taking protease inhibitors. There are no known drug 
interactions between rosuvastatin and non nucleoside 
reverse transcriptase inhibitors (NNRTIs).79
A large retrospective cohort study in America found 
that  rosuvastatin  produced  the  largest  reduction  in 
LDL-C, non-HDL-C and triglycerides when compared 
with atorvastatin and pravastatin. It also produced the 
highest proportion of patients achieving target LDL 
and non-HDL-C without a difference in toxicity pro-
file when compared with atorvastatin and pravastatin.80 
The British HIV association recommend the use of 
rosuvastatin in patients receiving HAART.77
safety
In the pooled safety data of controlled Phase II/II trials, 
the  incidence  of  adverse  events  during  rosuvasta-
tin therapy was comparable to those of other   statins. rosuvastatin—what role in cardiovascular disease prevention?
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Subsequent meta-analysis of clinical trials and post 
marketing  experience  have  consistently  shown  that 
rosuvastatin has a comparable safety profile to other 
available statins when used at 10 mg to 40 mg daily 
dose.8 In JUPITER, hepatic injury, myopathy and can-
cer did not occur more frequently with rosuvastatin than 
with placebo, despite the fact that LDL-C , 55 mg/dL 
(1.4 mmol/L) were achieved in half of the rosuvas-
tatin group.40 AURORA reported a high incidence of 
adverse and serious adverse events which is consistent 
with previous studies in haemodialysis patients.61
A recent large prospective cohort study of primary 
care patients from 368 general practices in England 
and Wales reported findings from 225,922 patients 
who  commenced  statin  therapy  between  2002  and 
2008. There were no clinically significant associations 
between any statins and Parkinson’s disease, rheuma-
toid  arthritis,  venous  thromboembolism,  dementia, 
osteoporotic  fracture,  gastric  cancer,  lung  cancer, 
melanoma, renal cancer, breast cancer and prostate 
cancer. The study further showed that with the excep-
tion of fluvastatin, all statins were associated with a 
dose dependent increased risk of myopathy. A direct 
comparison  test  between  the  individual  statins  did 
not yield a significant difference in men (P = 0.57) 
or women (P = 0.61). All statins were associated with 
a dose dependent increased risk of liver dysfunction. 
The highest risk was associated with fluvastatin while 
pravastatin  and  rosuvastatin  had  the  lowest  risks. 
Table 4 shows the hazard ratios of developing myo-
pathy or liver dysfunction with different statins.
Rosuvastatin at every prescribed dose compared 
favourably  with  other  statins  with  regard  to  liver 
  dysfunction, myopathy, cataract, oesophageal   cancer 
and  acute  renal  failure.81  A  meta-analysis  of  ran-
domised controlled trials on statins showed that there 
was a positive association between statins and the inci-
dence of diabetes. The combined data reported a 0.39% 
absolute risk of developing diabetes with 4 years of 
statin therapy. The risk was higher in older partici-
pants of the statin trials. The absolute risk of develop-
ing diabetes was 0.6% with rosuvastatin (JUPITER, 
CORONA),  0.4%  with  atorvastatin  (ASCOT-LLA) 
and 0.3% for simvastatin (4S). Paradoxically, there 
was a reduced incidence of diabetes with pravastatin 
(WOSCOPS, LIPID). It therefore appears that the risk 
of developing diabetes is marginally higher with rosu-
vastatin compared to other statins.82 Other studies that 
involved rosuvastatin such as JUPITER, CORONA 
and GISSI HF all had an increased incidence of diabe-
tes in the patients receiving rosuvastatin compared to 
placebo.40,72,73 The overwhelming benefit of statins in 
the reduction of cardiovascular events outweighs the 
small risk of developing diabetes therefore statin ther-
apy should be used in patients with high cardiovascular 
risk. All statins can cause myopathy and rhabdomyol-
ysis especially at higher doses.   Combination of statins 
with other medications may lead to increased risk if 
these medication increase plasma concentrations of 
the statins. Cases of rhabdomyolysis have been report 
in patients on medications which increase plasma con-
centrations of rosuvastatin such as gemfibrozil, lipo-
navir and ritonavir. Table 5 shows drugs which can 
interact with rosuvastatin.
One unique effect of rosuvastatin is the dose depen-
dent transient proximal isolated low-  molecular-weight 
Table 4. Adverse outcomes of statins.
Adverse outcomes statin Hazard ratio ♀ (95% CI) Hazard ratio ♂ (95% CI)
Moderate/severe  
myopathy
None 1.00 1.00
Simvastatin 3.30 (2.32–4.69) 6.11 (4.79–7.80)
Atorvastatin 2.62 (1.42–4.84) 8.18 (5.82–11.50)
Fluvastatin Insufficient data 1.20 (0.17–8.53)
pravastatin 2.68 (0.99–7.25) 5.79 (3.07–10.91)
rosuvastatin 5.41 (2.64–11.07) 4.19 (1.86–9.45)
Moderate/severe liver  
dysfunction
None 1.00 1.00
Simvastatin 1.62 (1.41–1.86) 1.79 (160–2.01)
Atorvastatin 2.00 (1.64–2.44) 1.86 (1.55–2.24)
Fluvastatin 3.08 (2.14–4.43) 2.37 (1.66–3.38)
pravastatin 1.91 (1.37–2.65) 1.13 (0.78–1.62)
rosuvastatin 1.31 (0.87–1.97) 1.46 (1.01–2.11)
Data from Hippisley-Cox et al.81Luvai et al
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proteinuria  which  appears  to  have  no  effect  on 
  glomerular function.
Efficacy
The STELLAR study showed the greater efficacy of 
rosuvastatin in improving LDL-C, triglycerides and 
HDL-C. It is the most effective statin at increasing 
HDL-C and has a positive effect on apolipoprotein 
and lipid ratios. Most of the lipid modifying benefit 
observed in the study was achieved at a 10 mg daily 
dose.46 PULSAR compared the efficacy and safety of 
rosuvastatin 10 mg with atorvastatin 20 mg in high risk 
patients with vascular occlusive disease.   Rosuvastatin 
10 mg was better than atorvastatin 20 mg at improv-
ing LDL-C, HDL-C, triglycerides and ApoB/ApoA-1 
ratio. It also enabled a greater proportion of treated 
patients to NCEP ATP III and ESC goals.49 Table 6 
compares the efficacy of different statins.
Intermittent rosuvastatin
Several small studies have reported that alternate-day 
therapy with rosuvastatin has important benefits in 
addition to improving the lipid profile. These include 
limitation of adverse reactions, enhanced patient com-
pliance and reduced cost of treatment.83 Other stud-
ies have looked at weekly rosuvastatin for patients 
with previous statin intolerance. One study achieved 
reductions of 23% in LDL-C, 17% in total choles-
terol, 12% in triglycerides and an increase of 5% in 
HDL-C in patients who had a prior history of adverse 
reactions to one or more statins.84 These alternative 
dosing regimens have not been proven to reduce car-
diovascular risk. A few studies have started report-
ing the effects of pulsed combination drug therapy 
involving rosuvastatin in their regimens.85
Combination therapy
Very high risk patients or those with severe dyslipi-
daemia often require combination therapy to achieve 
treatment goals and enhance lipid profile modifica-
tion. In one study combination of rosuvastatin 5 mg 
to 20 mg with fenofibric acid demonstrated signifi-
cant efficacy in lowering triglycerides and increasing 
HDL-C when compared with rosuvastatin alone. Fur-
thermore the combination of rosuvastatin with feno-
fibric acid was well tolerated and as safe as each drug 
used as monotherapy.86 Similar results were found by 
Durrington  when  combination  of  rosuvastatin  and 
fenofibrate  was  used  in  type  2  diabetes.87  Further 
clinical trials are required to establish the benefits 
in clinical outcomes of combination of rosuvastatin 
with fenofibrate. The use of rosuvastatin 40 mg with 
fenofibric acid or fenofibrate has not been evaluated 
and  should  therefore  not  be  prescribed  routinely.88 
Several studies have shown the efficacy and safety of 
rosuvastatin in combination with ezetimibe, bile acid 
sequestrants and fish oils.89,90 Some small trials and 
angiographic studies have demonstrated some benefit 
Table 5. rosuvastatin drug interactions.
Drugs that increase plasma concentrations  
of rosuvastatin
Drugs that antagonise organic anion transporting 
polypeptide 1B1
  Gemfibrozil
  protease inhibitors: ritonavir, liponavir
  Cyclosporin
Drugs that reduce plasma concentrations  
of rosuvastatin
  Antacids
  Erythromycin
Drugs affected by co-administration with rosuvastatin
  warfarin increased INr
  Ethinyl oestradiol: increased concentrations
Table 6. Efficacy of statins.
Comparative efficacy of statins
% LDL-C reduction Rosuvastatin Atorvastatin simvastatin pravastatin Fluvastatin Lovastatin
,25 5 10 5 10–20 20 10–20
25–35 5 10 10–20 20–40 40–80 20–40
35–45 5–10 10–20 20–40 80 80
45–55 10–20 20–40 80
55–60 20–40 80
60–65 40–80
Data from white.16rosuvastatin—what role in cardiovascular disease prevention?
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from combination therapy though this has not been 
corroborated by randomised clinical trial data.
Cost effectiveness
Economic evaluations show that intensive lipid low-
ering is a cost effective treatment for very high risk 
patients groups including those with ACS, heterozy-
gous FH and diabetes. For these purposes, rosuvasta-
tin 40 mg daily was the most optimal treatment based 
on 2009 prices for statins, providing generic atorvas-
tatin 80 mg was not available.91 A similar observation 
was made for lower treatment doses in the PULSAR 
trial. At the time of the study (2006), annual acqui-
sition costs were lower for rosuvastatin 10 mg than 
atorvastatin 20 mg in the UK and the US.49 Our group 
demonstrated in the GEOSTAT (Hepatic Metabolism 
and  Transporter  Gene  Variants  Enhance  Response 
to Rosuvastatin in Patients With Acute Myocardial 
Infarction) study that patients with CYP3A5 and/or 
BCRP variant genotypes who were treated with rosu-
vastatin achieved treatment targets more frequently 
than those on simvastatin 40 mg. These results indicate 
the potential value of genetic profiling of patients to 
optimise statin response in a cost effective manner.92
place in Therapy
Rosuvastatin is a potent statin with pharmacologic 
and  pharmacokinetic  advantages.  Its  high  affinity 
for OATP-1B1 ensure a high hepatocyte concentra-
tion which results in superior efficacy at lowering 
LDL-C and TG as well as improving HDL-C and 
ApoB:ApoA-1  ratio  compared  to  other  statins. 
A  possible  exception  is  pitavastatin.  Rosuvastatin 
is synthetic with a relatively low lipophilicity when 
compared with other statins and has minimal entry 
into peripheral cells. This, coupled with its minimal 
CYP450 metabolism confers relatively better toler-
ability, safety and drug interaction profile. As the cir-
culating half life is 19 hrs it can be taken once daily at 
any time of the day regardless of meals.
Clinical  trial  data  and  post  marketing  surveil-
lance have demonstrated important information about 
rosuvastatin. Several cardiovascular outcome studies 
have confirmed the beneficial effects that had been 
anticipated from vascular imaging studies. JUPITER 
showed the reduction in cardiovascular events and all 
cause mortality of rosuvastatin in primary prevention 
in patients with lower cardiovascular risk. This is the 
only statin that has been shown to reduce   cardiovascular 
and all cause mortality.40 Some authors believe that 
some of the benefits may have been exaggerated by 
the short duration of the study. Comparative studies 
have shown the potential benefits of rosuvastatin in 
secondary prevention and high intensity therapy.46,49 
The long term and legacy effects of rosuvastatin on 
cardiovascular mortality are awaited. A small increase 
in diabetes among those .65 years has been observed 
in rosuvastatin trials, but this occurs with other statins 
with the exception of pravastatin.78 Physicians should 
be aware of the risk of proteinuria in patients on rosu-
vastatin and should screen for this. Given its potency 
and safety, rosuvastatin is a versatile statin that can be 
used in different clinical contexts.
Patients  with  a  10  year  cardiovascular  risk 
of  .20%  require  intensive  treatment  to  achieve 
LDL-C ,2 mmol/L or a .50% reduction from base-
line. These include patients with established CHD, 
moderate to severe CKD, type 1 and type 2 diabe-
tes. Only rosuvastatin 20 mg–40 mg and atorvastatin 
80 mg achieve this reduction as monotherapy. A large 
proportion of these patients are on multiple drug ther-
apy and thus it is crucial to limit pill burden and avoid 
drug interactions. Most lipid therapy is now aimed at 
achieving treatment goals from guideline bodies such 
as ESC, JBS and NCEP ATP III. A new category of 
patients is thus created by those who fail to achieve 
these  goals  with  various  treatments.  Such  patients 
should be considered for treatment with rosuvastatin.
Special groups
Patients with hereditary hyperlipidaemia, particularly 
FH and FCH should be considered for early treatment 
with rosuvastatin. Their baseline LDL-C is invariably 
too high for less potent statins to reduce adequately. 
Furthermore  these  patients  are  at  extremely  high 
cardiovascular risk. Patients on HAART should be 
considered for treatment with rosuvastatin whenever 
their treatment allows. In this patient group, choice 
is often limited and determined by the anti-retroviral 
regimen. They are also at very high cardiovascular 
risk. Certain patient groups such as those with renal 
failure and the elderly are at increased risk of statin 
related myopathy and rhabdomyolysis. Because of its 
potency, rosuvastatin can be used at very low doses. 
A  number  of  reports  are  emerging  about  intermit-
tent or pulsed therapy which is better tolerated yet Luvai et al
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  maintains  reasonable  lipid  control.  As  with  other 
potent statins, lower doses of rosuvastatin should be 
used in patients from South East Asia to reduce risk 
of rhabdomyolysis.
In conclusion rosuvastatin is an effective and safe 
statin which is ideal second line treatment for most 
patients requiring primary or secondary prevention. 
When there is a history of previous statin intolerance 
or multiple drug therapy, low dose rosuvastatin may 
be considered. For patient groups at very high risk 
where stringent LDL-C reduction is envisaged, rosu-
vastatin should be considered as a potential first line 
treatment. Its benefits against cost in patients with 
lower cardiovascular risk remain an issue of debate.
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